Temsirolimus is under clinical development by Pfizer and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer). According to GlobalData, Phase II drugs for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) have a 45% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Temsirolimus’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Temsirolimus overview
Temsirolimus (Torisel) an ester analog of rapamycin, is a antineoplastic agent. It is formulated as concentrated solution for injection for intravenous administration. Torisel is inicated for the treatment of advanced renal cell carcinoma. It is also indicated for the treatment of mantle cell lymphoma.
The drug candidate is under development for the treatment of the B-cell acute lymphoblastic leukemia, peripheral T-cell lymphoma, HER2 positive metastatic breast cancer, triple-negative breast cancer, lymphoblastic lymphoma, bladder cancer, malignant glioma, glioblastoma multiforme. It was also under development for the treatment of breast cancer, CNS lymphoma, Hodgkin lymphoma, follicular lymphoma, myelodysplastic syndrome, rheumatoid arthritis, relapsing remitting multiple sclerosis and secondary progressive relapsing multiple sclerosis. It was also under development for the treatment of advanced hepatocellular carcinoma, T-cell acute lymphoblastic leukemia, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, ovarian cancer and medullary thyroid cancer.
Pfizer overview
Pfizer discovers, develops, manufactures, and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, women’s health, cancer, inflammation, immune disorders, and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, individual provider offices, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa, and the Middle East. Pfizer is headquartered in New York, the US.
For a complete picture of Temsirolimus’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
